Another thought on the diagnostic test after reading the SAVA earnings report today. There are several CNS companies "developing" diagnostic tests based on their specific MOAs. Only makes sense. What Alkon's original crew has done is advance the testing kit to the foreground and actually is already in sales. They received breakthrough device designation a couple years ago and have now raised over 10 million dollars as a private company. That speaks to me that there is a lot of confidence in the synaptic issues theory in AD and the ability to diagnose and to monitor. Other CNS companies seem to have "hopeful" diagnostic tests IF their drug proves efficacy. Just a thought.
News 
Market Data 
Discover 
